本文選題：調強適形放療同步化療　切入點：復發(fā)性宮頸癌　出處：《中國老年學雜志》2017年06期 　論文類型：期刊論文

【摘要】：目的探討調強適形放療同步化療(IMRTCC)治療復發(fā)性宮頸癌的療效及安全性。方法 88例復發(fā)性宮頸癌患者按簡單數(shù)字隨機表法分為觀察組及對照組各44例,觀察組給予IMRTCC方案治療,對照組單純給予常規(guī)三維適形放療,隨訪6個月,對比兩組療效、不良反應及近期生存率及轉移率。結果觀察組總有效率明顯高于對照組,白細胞下降為Ⅱ~Ⅲ級的發(fā)生率明顯低于對照組(均P0.05)。兩組治療3、6個月后生存率及轉移率比較差異無統(tǒng)計學意義(P0.05)。結論利用IMRTCC對復發(fā)性宮頸癌患者進行治療,具有較高的療效,且安全性也較好,值得臨床應用。
[Abstract]:Objective to investigate the efficacy and safety of IMRT IMRTCC in the treatment of recurrent cervical cancer by intensity modulated conformal radiotherapy (IMRT). Methods 88 patients with recurrent cervical cancer were divided into two groups according to simple digital random table method: the observation group (n = 44) and the control group (n = 44). The control group was treated with conventional three-dimensional conformal radiotherapy and followed up for 6 months to compare the curative effect, adverse reaction, short-term survival rate and metastasis rate. Results the total effective rate in the observation group was significantly higher than that in the control group. The incidence of leukocytopenia in grade 鈪，

本文編號：1628576